
Cabaletta Bio fell 59.3% from $2.30 to $0.94, behind the S&P 500's +3.2%. Its worst day was Nov 16 (−13.3%), and its low came Nov 20 at $0.94.
Nov 24, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Cabaletta Bio shares rose 25.6%, while the S&P 500 rose 0.5%.
+25.6%, on 30M shares, the year's heaviest volume · S&P 500 +0.5%
Cabaletta Bio shares rose 13.4%, while the S&P 500 rose 0.7%.
+13.4% · S&P 500 +0.7%
Story events cover the past 12 months · Times ET
EPS of $-0.40 beat the $-0.46 estimate on $0.00 revenue (est. $833,330.00).
−4.1% · S&P 500 +1.1%
Cabaletta Bio closed at its highest level of the year, 80.4% above where the year started.
+8.4% · S&P 500 +0.8%
EPS of $-0.39 beat the $-0.39 estimate on $0.00 revenue.
+0.6% · S&P 500 +0.8%
EPS of $-0.34 beat the $-0.35 estimate on $0.00 revenue.
−4.9% · S&P 500 +0.7%
EPS of $-0.28 beat the $-0.31 estimate on $0.00 revenue.
−9.9% · S&P 500 −4.4%
Where it ended: a close of $0.94 on Nov 20, 2026. Up next: Q4 2026 earnings on Mar 22, 2027 (EPS est. $-0.28).
Nothing in the past 12 months.
All CABA dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CABA and SPY from Benzinga historical bars. Not investment advice.